NEKTAR THERAPEUTICS (NKTR)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 500M 1B 1.5B FY16: 165.4M FY17: 307.7M FY18: 1.2B FY19: 114.6M FY20: 152.9M FY21: 101.9M FY22: 92.1M FY23: 90.1M FY24: 98.4M FY25: 55.2M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

0 400M 800M 1.2B FY16: 135.2M FY17: 277.2M FY18: 1.2B FY19: 93.2M FY20: 133.4M FY21: 77M FY22: 70.4M FY23: 56.4M FY24: 67.7M FY25: 55.2M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Income Annual

-500M -250M 0 250M 500M 750M FY16: -112.9M FY17: -59.6M FY18: 687.9M FY19: -440M FY20: -425.1M FY21: -446.1M FY22: -376.2M FY23: -263.7M FY24: -105.2M FY25: -140.1M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Net Income Annual

-750M -500M -250M 0 250M 500M 750M FY16: -153.5M FY17: -96.7M FY18: 681.3M FY19: -440.7M FY20: -444.4M FY21: -523.8M FY22: -368.2M FY23: -276.1M FY24: -119M FY25: -164.1M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Cost of Revenue Annual

0 15M 30M 45M FY16: 30.2M FY17: 30.5M FY18: 24.4M FY19: 21.4M FY20: 19.5M FY21: 24.9M FY22: 21.6M FY23: 33.8M FY24: 30.7M FY25: 0 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-500M -250M 0 250M 500M 750M FY16: -117M FY17: -80.4M FY18: 718.2M FY19: -328.7M FY20: -313.3M FY21: -412.7M FY22: -304M FY23: -192.6M FY24: -175.7M FY25: -208.5M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-500M -250M 0 250M 500M 750M FY16: -123.4M FY17: -90.1M FY18: 704M FY19: -355M FY20: -320.5M FY21: -427.6M FY22: -309.7M FY23: -193.5M FY24: -177.2M FY25: -208.7M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 70M 140M 210M FY16: 139.6M FY17: 156M FY18: 180.1M FY19: 175M FY20: 178.6M FY21: 183.3M FY22: 187.1M FY23: 190M FY24: 13.7M FY25: 16.9M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-900.00 -600.00 -300.00 0.00 300.00 600.00 900.00 Q3 '16: -1.22 Q4 '16: -1.10 Q1 '17: -1.38 Q2 '17: -1.41 Q3 '17: -0.72 Q4 '17: -0.65 Q1 '18: -0.83 Q2 '18: 4.89 Q3 '18: 3.96 Q4 '18: 3.60 Q1 '19: 3.51 Q2 '19: -2.45 Q3 '19: -2.45 Q4 '19: -2.52 Q1 '20: -2.61 Q2 '20: -2.43 Q3 '20: -2.48 Q4 '20: -2.49 Q1 '21: -2.39 Q2 '21: -2.63 Q3 '21: -2.72 Q4 '21: -792.07 Q1 '22: -791.88 Q2 '22: -792.04 Q3 '22: -791.65 Q4 '22: -1.97 Q1 '23: -2.21 Q2 '23: -1.63 Q3 '23: -1.56 Q4 '23: -1.46 Q1 '24: -0.92 Q2 '24: -4.41 Q3 '24: -6.83 Q4 '24: -8.68 Q1 '25: -12.11 Q2 '25: -11.30 Q3 '25: -10.51 Q4 '25: -10.03 Q1 '26: -8.23 Q2 '26: -6.51 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.